The fundamental purpose of Ваксигрип is commonly used to help with specific immunoprophylaxis by reducing the risk of illness caused by the seasonal influenza virus strains contained in the vaccine formulation. Annual vaccination is considered a relevant strategy to help reduce the risk of flu illnesses, hospitalizations, and severe outcomes. This protective strategy is applied in addressing the potential for illness, and is not a treatment for an established active infection.

Primary Prophylactic Focus

This vaccine is considered relevant for managing conditions associated with acute or disruptive episodes of the flu, particularly where symptoms related to systemic imbalance may intensify temporarily. The primary therapeutic benefit is commonly used to help with the reduction in the likelihood of developing severe, complicated forms of the disease, such as pneumonia.

“This proactive measure may assist with the reduction of the risk of acute febrile illness and the symptoms that are characteristic of the flu.”

This assists with maintaining functional stability and may help patients cope more steadily with the potential for pronounced manifestations. The vaccine is considered relevant for individuals at high risk, including older adults and those with chronic health conditions, where infection poses a compounded threat to health stability.

Quick Fact: Support for Symptomatic Periods

The vaccine supports general well-being and may be part of symptomatic management by reducing the risk of developing the acute, debilitating symptoms related to physical discomfort and high physiological activity associated with severe influenza.

Brief Listing of Indications

The primary therapeutic use is applied in addressing the need for protection against the circulating strains of seasonal influenza virus, particularly targeting the reduction of risk for severe infection, severe, potentially serious complications, and the need for hospitalization in vulnerable populations, including older adults and patients with chronic underlying conditions.

Who can and cannot use Ваксигрип?

Eligibility for Ваксигрип (or Vaxigrip Tetra) is defined by official regulatory labeling, covering specific age groups, medical conditions, and physiological states.

Eligibility Scope

Eligibility-Related Restrictions

The vaccine should be administered with caution in individuals with a bleeding disorder or thrombocytopenia due to the risk of bleeding from the intramuscular injection. Patients with a history of Guillain-Barré Syndrome (GBS) following a previous influenza vaccine require careful consideration of benefits versus risks before use. Individuals with compromised immune systems may have an insufficient antibody response.

The interaction profile for Ваксигрип is defined by pharmacodynamic interference and documented procedural requirements for co-administration. Regulatory documents state that when the vaccine is co-administered with immunosuppressant treatments, including those used for immunodeficiency or following organ transplantation, the intended immunological response may be reduced or insufficient. This is a critical pharmacodynamic interaction affecting the vaccine's protective effect.

The vaccine has been documented for co-administration with other vaccines such as the pneumococcal polysaccharide vaccine. When given concomitantly with another vaccine, official regulatory information specifies that separate injection sites and separate syringes must be used, which is a mandatory administration-timing and physical separation rule.

Regarding substances, use is formally restricted if the recipient has a documented hypersensitivity to trace components present in the final product, including eggs (ovalbumin), neomycin, formaldehyde, and octoxinol-9.

A notable procedural constraint involves diagnostic products. Following vaccination, regulatory authorities have documented that the vaccine may cause transient false positive results in ELISA serology tests used to detect antibodies for specific viruses, including HIV1, Hepatitis C, and HTLV1. These false results are attributable to the vaccine-induced transient IgM antibody response, a phenomenon that the Western Blot technique typically disproves. The profile contains no documented pharmacokinetic interactions, such as CYP-enzyme or transporter-mediated effects, with other medicines.

Ваксигрип is a vaccine composed of purified surface antigens, specifically hemagglutinin (HA) and neuraminidase (NA), corresponding to the current seasonal influenza virus strains. These antigens are introduced to the host immune system via an intramuscular or subcutaneous route. The presence of the viral antigens triggers an adaptive immunological cascade. This cascade involves the uptake and presentation of the antigens by antigen-presenting cells (APCs) to T-helper lymphocytes. Activation of the T-helper cells leads to the differentiation and proliferation of B lymphocytes into plasma cells. These plasma cells synthesize and secrete circulating antibodies specific to the HA and NA epitopes. The resulting antibody pool functions by coating the homologous influenza virus particles, preventing the HA protein from binding to sialic acid receptors on host respiratory epithelial cells. This neutralization prevents viral attachment and subsequent cell entry, thereby inhibiting the initiation of the viral replication cycle within the respiratory tract.

How to Use Vaxigrip (Influenza Vaccine)

This section outlines the administration instructions for Vaxigrip (including the quadrivalent version, VaxigripTetra).

Administration Protocol

Population-Specific Dosing and Procedures

Specific protocols are defined based on age and prior vaccination status:

• Children 6 months to less than 9 years (Primary Vaccination): Children in this age group who have not been previously vaccinated against influenza require a second 0.5 mL dose. This second dose must be given after an interval of at least four weeks following the first dose.
• Injection Site: For adults and children 36 months and older, the preferred injection site is the deltoid muscle of the upper arm. For infants and toddlers (6 to 35 months), the injection is administered into the anterolateral aspect of the thigh.

Preparation Requirements

Prior to administration, the pre-filled syringe containing the suspension should be shaken gently to ensure a uniform mixture. The vaccine must be visually inspected for any particulate matter or discoloration before use. If administered simultaneously with other vaccines, separate injection sites and separate syringes must be used.

Research Evidence / Overview of Studies for Ваксигрип

Evidence for Specific Immunoprophylaxis against Seasonal Flu

Research on the inactivated influenza vaccine was studied for its role in providing specific immunity against seasonal flu strains. The evidence landscape comprises Randomized Controlled Trials (RCTs) and specialized Phase III immunogenicity trials involving populations of healthy adults, older adults, and children. These studies monitored the short-term response to the vaccine by measuring the level of protective antibodies (known as the seroprotection rate and seroconversion rate) created in the body. Trials described that the measurements for antibody response were consistent with pre-established regulatory criteria for the flu strains it contained. In real-world settings, observational studies have also explored the patterns of outcome in participants over a full flu season, tracking the incidence of laboratory-confirmed influenza infection. This research contributes to the broader evidence landscape by providing insight into how the vaccine was evaluated in various study environments.

Evidence in High-Risk Groups and for Severe Outcomes

Research was evaluated in specific populations where flu infection presents conditions associated with acute or disruptive episodes, such as older adults and individuals living with chronic underlying conditions. These studies examined outcomes related to systemic or functional imbalance, specifically looking at how the vaccine was associated with patterns of lower rates of flu-related hospitalization. Research has also explored outcomes describing episodic or acute changes, such as the development of severe, complicated forms of the disease. Findings indicate that observed patterns often rely on data collected over several seasons, and research describes that certain populations, such as those with significant chronic conditions, were observed in some studies monitoring physiological strain or stress.

Research on Protection through Maternal Immunization

Studies monitored the potential for the vaccine to provide passive protection to infants who are too young to be vaccinated themselves. This research was studied for women who received the vaccine during pregnancy. The trials examined the transfer of antibodies from the mother to the developing fetus; researchers monitored antibody levels in the newborn's cord blood. Research describes that antibody transfer was observed in some studies, and findings help contextualize how the vaccine was associated with patterns of lower infection rates in these infants, although evidence is limited regarding the precise duration or consistency of this passive protection.

Durability of Response and Follow-up Duration in Studies

The duration of monitoring in the core regulatory studies was observed in defined, generally short-term time intervals for initial antibody measurements. For clinical outcomes like infection rates, studies typically track participants over the duration of a single influenza season. The evidence landscape currently has limited information for long-term outcomes, meaning that data on the continued presence of antibodies or the durability of the immune response extending past the immediate season is not fully established. Researchers continue to monitor and explore the durability of the immune response over extended periods, contributing to ongoing research.

Limitations and Areas of Research Uncertainty

While the research contributes to the broader evidence landscape, certain limitations exist. The results apply only to the populations studied, and findings can be mixed, especially when comparing specific age groups. A key challenge is the annual requirement for vaccine strains to match the circulating virus; if a mismatch occurs, the ability to draw conclusions about performance becomes uncertain. Additionally, subgroup findings are uncertain or data for certain groups remain insufficient, particularly for patients with compromised immune systems. Research highlights that studies focusing on severe outcomes are often observational, and these types of designs are susceptible to confounding factors that complicate interpretation. Long-term effects and outcomes over many seasons are not fully established.

Common questions about Ваксигрип (FAQ)

Q: Can I drink alcohol while taking this medicine?

A: Official information indicates that this medicine should be used with caution in patients with hepatic disease or alcoholism. Drinking alcohol may increase the risk of certain side effects, such as nausea and headache. Regulatory caution exists regarding potential additive risks, as the medication and alcohol may both affect liver function.

Q: Does this medication make you sleepy or affect your concentration?

A: Regulatory documents list potential neurological disorders and neuropsychiatric reactions as possible effects. These may include symptoms that affect mental state or movement. Label information also notes that hypoglycemia (low blood sugar) is a potential effect, which may cause temporary symptoms like dizziness and confusion.

Q: How should I store my medication?

A: Store the tablets at room temperature, which is typically between 68^circF to 77^circF (20^circC to 25^circC). The product information states the container should be kept tightly closed. The tablets must also be stored in a dry place and protected from light.

Q: Is it safe to take this while pregnant or breastfeeding?

A: Regulatory information advises that the drug should be used during pregnancy only if the potential benefit justifies the potential risk to the developing fetus. The medicine does cross the placenta. The drug is present in human milk, and official information indicates that a decision must be made, in consultation with a healthcare professional, regarding discontinuing nursing or discontinuing the medication.

Q: Who should not take this medicine (Contraindications)?

A: This medicine is contraindicated in patients with a known hypersensitivity or severe allergic reaction to 4-aminoquinoline compounds or any other components of the tablets. It is also contraindicated in patients who have a pre-existing maculopathy (disease affecting the central part of the retina) in the eye.

Q: Is this medication safe for long-term use?

A: Due to the potential for irreversible retinal damage and issues affecting the heart muscle (cardiomyopathy), the official prescribing information requires regular monitoring during long-term therapy. This includes a baseline ocular exam followed by periodic ocular exams, often at least every 12 months.

Q: Can children 2 years old use this medicine?

A: The FDA label includes dosing information for pediatric patients for malaria treatment. However, the EMA SmPC specifically warns that small children are particularly sensitive to the toxic effects of 4-aminoquinolines. The product information includes a safety warning for caregivers to keep the medicine out of the reach of children to prevent accidental overdose.

How to Store and Dispose of Vaxigrip

Official regulatory documents establish mandatory storage and handling requirements to maintain the stability of Vaxigrip, an inactivated viral vaccine.

Storage Requirements

Disposal Instructions

Do not dispose of Vaxigrip (unused medicine or waste materials) via household waste or by flushing it into wastewater. Disposal must adhere to local requirements for pharmaceutical waste, which typically involves consulting a pharmacist or nurse for the appropriate collection method. Opened multidose vials, if applicable, must be discarded seven days after first use.